As a proof of concept study to identify multi-target kinase BET bromodomain compounds we focused on EGFR TKD and BRD4(1) as a starting point for identifying more efficacious compounds targeting cancers containing an EGFR amplification. This evidence concerns the gene BRD4 and cancer.